Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Metformin use does not worsen GI symptoms with GLP-1RA
Last updated July 4, 2026
Key finding
Concomitant metformin use did not increase the percentage of participants who developed gastrointestinal adverse events.
This study evaluated the impact of concomitant metformin use on gastrointestinal adverse events during GLP-1 receptor agonist initiation, finding no increase in adverse events.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the impact of concomitant metformin use on gastrointestinal adverse events during GLP-1 receptor agonist initiation, finding no increase in adverse events.
Clinical relevance
These findings are significant for clinicians managing patients with diabetes who may require both metformin and GLP-1 receptor agonists. Understanding that metformin does not exacerbate gastrointestinal side effects can help in making informed treatment decisions, potentially improving patient adherence and outcomes.
Keep in mind
The study's sample size and demographic diversity were not specified. Results may not be generalizable to all patient populations. Potential unmeasured confounders could affect outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Klara RK, Kim KC, Edwin F, Søren O, Trine A, Ildiko L. Concomitant Metformin Use Does Not Increase Gastrointestinal Adverse Events During GLP-1RA Initiation. Diabetes Care. 2024;47(2):280-284. doi:10.2337/dc23-1791
Main Effects
Concomitant metformin use did not increase the incidence of gastrointestinal adverse events.
There was no increased risk of nausea associated with metformin use.
Metformin did not elevate the risk of vomiting among participants.
Study product discontinuation due to gastrointestinal adverse events was not higher with metformin.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Metformin and Adverse events incidence, Gastrointestinal disorders incidence.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
- Adverse events incidence
- Gastrointestinal disorders incidence
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
2
Evidence pairs
2
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 57
2
Related topics
2
Evidence pairs
165
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 2 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Metformin Therapies and Gastrointestinal Adverse Events
Related evidence
Evidence topic
Adverse Events and Safety
Save evidence
Evidence topic
Metformin
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Gastrointestinal disorders incidence
Metformin → Gastrointestinal disorders incidence
Metformin → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Metformin did not increase gastrointestinal adverse events during GLP-1RA initiation.
- No association was found between metformin and increased nausea risk.
- Study product discontinuation due to GI issues was not higher with metformin.
Who this applies to
- Adults with type 2 diabetes requiring GLP-1 receptor agonists.
- Patients currently taking metformin for diabetes management.
Keep in Mind
- The study design may limit the applicability of findings to broader populations.
- Results are specific to the context of GLP-1 receptor agonist initiation.
- Further research may be needed to confirm findings in diverse populations.
Between the Lines
- The study's sample size and demographic diversity were not specified.
- Results may not be generalizable to all patient populations.
- Potential unmeasured confounders could affect outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Adverse events incidence, Metformin Therapies and Gastrointestinal Adverse Events.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Adverse events incidence Evidence Hub
All studies measuring Adverse events incidence
1 studies
outcome_hubMeasures Adverse events incidence as a key outcome.
Gastrointestinal Adverse Events Evidence Hub
All studies measuring Gastrointestinal Adverse Events
1 studies
outcome_hubMeasures Gastrointestinal Adverse Events as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
1 studies
intervention_hubContributes to Metformin Therapies evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and Adverse events incidence
Intervention: MetforminOutcome: Adverse events incidence
1 results
All studies on Metformin and Gastrointestinal disorders incidence
Intervention: MetforminOutcome: Gastrointestinal disorders incidence
1 results
All studies on Metformin
Intervention: Metformin
1 results
All studies measuring Adverse events incidence
Outcome: Adverse events incidence
1 results
All studies measuring Gastrointestinal disorders incidence
Outcome: Gastrointestinal disorders incidence
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies affect gastrointestinal adverse events?
Emerging Evidence
Current evidence does not show a clear benefit of Metformin Therapies for Gastrointestinal Adverse Events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin affect adverse events incidence?
Emerging Evidence
Current evidence does not show a clear benefit of Metformin for Adverse events incidence.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Adverse events incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Vildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesEarly use of effective therapies may improve diabetes outcomesPremeal metformin improves postmeal glucose control in diabetes.Metformin may reduce prandial insulin needs in pregnant women with type 1 diabetesSitagliptin with Metformin Improves Metabolic Health
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.